Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Launches US Sales Team

Premium

Rosetta Genomics this week announced that it has established a US sales team that will handle the commercialization of its suite of microRNA-based diagnostics.

The team will particularly focus on Rosetta's miRview Mets and miRview Mets 2 tests, which are designed to determine the source of cancers of unknown primary origin.

Rosetta did not specify the size of the team, but said it will expand it “over the coming quarters.”

The move has long been expected after a dispute between Rosetta and its one-time US distribution partner Prometheus Laboratories resulted in the miRNA company regaining the market rights to its products (GSN 12/2/2010). Rosetta continues to sell its products through distributors outside of the US.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.